OTC Version Of Santarus' Zegerid Approved
December 02, 2009 at 12:22 PM EST
The Food and Drug Administration approved an over the counter version of Santarus Inc.'s (Nasdaq: SNTS) heartburn treatment Zegerid made by Merck & Co. Inc. (NYSE: MRK). Shares of Santarus climbed 62 cents to $4.91 while Merck stock eased 28 cents to $36.60.
